

# NEWS RELEASE



**FOR IMMEDIATE RELEASE**

## **Contacts:**

Troy Kirkpatrick  
BD Public Relations  
858.617.2361  
[troy.kirkpatrick@bd.com](mailto:troy.kirkpatrick@bd.com)

## **BD Announces Results of Third-Party Voluntary Stack Testing at Covington Facility**

### ***Emissions Abatement Technology Tested at Greater Than 99.999% Destruction Rate Efficiency, Better Than Previous Performance Test***

**COVINGTON, Ga. (Oct. 3, 2019)** – BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced that a third-party emissions testing firm has determined that the emissions abatement technology used at BD's Covington facility destroys 99.999% of ethylene oxide (EtO) routed to the abatement system during the medical product sterilization process. This destruction rate efficiency (DRE) is significantly better than the 99.97% reported during the last required stack test in 2012.

The voluntary stack test was conducted by the independent, analytical firm, ECSI of San Clemente, California, on September 11 and 12. The test protocol was accepted by the Georgia Environmental Protection Division (EPD) prior to the test, and two members of Georgia EPD's Source Monitoring Unit were onsite to observe the test. Based on this most recent performance test, BD would have reported only 3.5 pounds of EtO point source emissions for the full year (0.15 ounces per day), which is 28 times lower than BD's previously reported 100.7 pounds of EtO point source emissions from Covington in 2018.

The results are not from the facility operating its emissions reduction equipment in a different way. The reported increase in efficiency is the result of more sensitive, higher resolution testing equipment that can detect and measure EtO levels at much lower concentrations than previous technology.

"The results of the latest stack test confirm that we operate our facility in a safe and responsible way, with newer, more sophisticated technology confirming that our stack emissions are extremely low," said Ellen Kondracki, vice president of Environment, Health and Safety at BD. "Given these new test results, it can be inferred that past emission reporting from BD (and previously C. R. Bard, Inc.) overestimated the amount of EtO released from our stacks, and historic reported emissions would have been significantly lower if prior stack testing had the ability to detect to today's level of precision. With stack testing confirming emissions to be lower than expected, we have turned our focus to the previously announced \$8 million investment for planned improvements to further reduce fugitive

emissions from the facility, and we are on schedule to submit our permit application on or before the end of the month.”

Because emissions modeling from U.S. Environmental Protection Agency and Georgia Environmental Protection Division are based on emissions reported using the DRE from the previous stack test, the modeling results from the 2018 National Air Toxics Assessment and Georgia EPD’s modeling exercise from June 2019 would have shown significantly lower emissions in their models as well.

Using the updated 99.999% destruction efficiency, BD estimates 2019 emissions from the stack will be approximately 3 to 5 pounds. BD will report 2019 emissions through the U.S. Environmental Protection Agency’s (EPA) Toxic Release Inventory using the updated destruction rate by July 1, 2020, in accordance with EPA requirements. BD does not intend to restate reported emissions from 2018 or earlier based on the results of this stack test.

# # #

#### **About BD**

BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 65,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit [bd.com](http://bd.com).